Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: de-104, belumosudil, fasudil +10 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 21 Parkinson's papers of 1,548 | 0.59 |
| pathways Reactome | 12 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5026
Sealed predictions
- ROCK2 in dopamine neurons, braak+0.38 (p 0.311) → -0.37 (p 0.334)receipt 5034
Swarm cases
receipt 5034: ROCK2 in dopamine neurons, braak
- power
- full sample -0.09 (p 0.728, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.12 (p 0.646, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.15 (p 0.549, n 18). could be the mix.
- skeptic
- leave-one-out range -0.21 to +0.03, sign flips 2; without severely affected donors -0.09 (p 0.728, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ROCK2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts